ABHICAP (ABHICAP) Fair Value & Analysis
IN · Market cap ₹697M
Fair value as of: Jul 5, 2026
From 14 valuation models · updated today
Share price −10.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹100.60 – ₹179.85 · fair‑value band ₹45.76 – ₹79.39 · the ₹100.60 price screens above the ₹63.51 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ABHICAP (ABHICAP) currently trades at ₹100.60, while our model-based Fair Value estimate is ₹63.51 — implying the stock looks roughly 36.9% overvalued today. We read business quality at 51/100 (solid quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, ABHICAP generated revenue of ₹42.8M at a net margin of 60.4%. Revenue grew 0.2% year over year. It earns a return on equity of 3.4%. Net debt stands at ₹12.6M. Fundamentals as of Jul 5, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
ABHICAP reported revenue of ₹42.8M in FY2026 versus ₹24.2M in FY2022, a compound +15.3%/yr. Reported net income was ₹25.9M in FY2026, compounding −13.8%/yr from FY2022.
Is ABHICAP fairly valued? → Check now
Explore undervalued stocks
Frequently asked questions
Is ABHICAP (ABHICAP) undervalued?
What is the fair value of ABHICAP?
What is the quality score of ABHICAP?
What is the revenue of ABHICAP (ABHICAP)?
What is the net profit margin of ABHICAP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.